Our development pipeline

DEVELOPMENT pipeline

Oncology

SOLID TUMORS

Compound / MOA

Project

Therapeutic area

Phase

Vorasidenib

S95032

Solid tumors

DPC

1

2

3

Ivosidenib

S95031

Solid tumors (new indication)

DPC

1

2

3

Darovasertib

S247629

Uveal melanoma

DPC

1

2

3

Partner

Vorasidenib + temozolomide

S95032

Solid tumors

DPC

1

2

3

Vorasidenib + pembrolizumab

S95032

Solid tumors

DPC

1/2

3

Ivosidenib + Durvalumab + Gemcitabine/Cisplatine

S95031

Solid tumors (new indication)

DPC

1/2

3

Anti-TIM3 combo

S95018

Non-small Cell Lung Cancer

DPC

1/2

3

Anti-CD73 combo

S95024

Non-small Cell Lung Cancer

DPC

1/2

3

Anti-NKG2A combo

S95029

Non-small Cell Lung Cancer and Gastric cancer

DPC

1/2

3

MAT2A inhibitor

S95035

Solid tumors

DPC

1

2

3

RAF/RAS inhibitor

S241656

2nd line Non Small Cell Lung Cancer

DPC

1

2

3

ND

S234821

Solid tumors

DPC

1

2

3

HEMATOLOGICAL MALIGNANCIES

Compound / MOA

Project

Therapeutic area

Phase

Ivosidenib + 7+3 (chimio)

S95031

Hematological malignancies (new indication)

DPC

1

2

3

Ivosidenib

S95031

Hematological malignancies (new indication)

DPC

1

2

3

Calaspargase pegol combo

S95015

Hematological malignancies (new indication)

DPC

1

2

3

Cemacabtagene ansegedleucel (Cema-Cel)
Anti-CD19 Allogeneic CAR-T*

S95023*

Diffuse Large B-Cell Lymphoma

DPC

1

2

3

Partner

Licensed from Cellectis and Sub-Licensed to Allogene*

Menin inhibitor

S243249

R/R Acute Myeloid Leukemia and R/R Acute Lymphoblastic Leukemia with KMT2A rearrangement or NPM1 mutations

DPC

1

2

3

ADC CD74-Mcl1 inihibitor + Venetoclax

S227928

R/R Acute Myeloid Leukemia and R/R Chronic Myelomonocytic Leukemia

DPC

1

2

3

Partner

ND

S236220

Hematological malignancies

DPC

1

2

3

Neurology

PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, ND= Not disclosed
R/R = Relapsed/Refractory
*Cema-Cel (ALLO501.A /S 95023) utilize TALEN® gene-editing technology owned by Cellectis. Servier, which has an exclusive license to the anti-CD19 investigational products from Cellectis, has granted Allogene exclusive rights to develop and commercialize Cema-Cel in the U.S., all EU Member States and the United Kingdom. For other candidate products (UCART19v1 and ALLO 501) sub-licensed to Allogene,  the ongoing activities are limited to follow up of patients from discontinued trials as per regulatory obligations.